What Information Fulfills EDSP Screening Requirements?

Slides:



Advertisements
Similar presentations
Health and Safety Executive Ecotoxicology Annex II and III data requirements Mark Clook Chemicals Regulation Directorate Health and Safety Executive UK.
Advertisements

Dra. Argelia Castaño Ministry of Science and Technology National Institute Food and Agrarian Research (INIA) Animal Health Research Center (CISA) Dra.
Framework for the Ecological Assessment of Impacted Sediments at Mining Sites in Region 7 By Jason Gunter (R7 Life Scientist) and.
Perspectives from EPA’s Endocrine Disruptor Screening Program
A Two-Tiered-Testing Decision Tree for Assays in the USEPA-EDSP Screening Battery: Using 15 years of experience to improve screening and testing for endocrine.
Endocrine Disruptor Screening Program: Ralph L. Cooper Endocrinology Branch Reproductive Toxicology Division NHEERL, U.S. EPA Male and Female Pubertal.
Evaluating Existing in vitro Endocrine Data Jeff Pregenzer, Director of Endocrine Studies, CeeTox.
UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014
Richard A. Becker, Ph.D., D.A.B.T American Chemistry Council Arlington, Virginia Comments on “Dose Setting” EDMVS Meeting July 23-24, 2002.
1 Post-UNEP/WHO EDC State of the Science 2012 report Personal reflections by Åke Bergman, coordinator of the above mentioned report, IPCP vice chair and.
Session III: Assessing Cumulative Effects of Endocrine Active Substances 9:15 - 9:30 Introduction” Rick Becker (Session Chair and Panel Moderator) 9:30.
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
June 2010 LANDSIEDEL 1 Chemical Industries Role in Tomorrows Toxicity Testing Robert Landsiedel, Susanne Kolle, Tzutzuy Ramirez, Hennicke Kamp and Ben.
Priority-setting for the Endocrine Disruptor Screening Program: Pesticide Active Ingredients Penelope A. Fenner-Crisp Office of Pesticide Programs U.S.
National Pesticide Program A New Toxicology Testing Paradigm: Meeting Common Needs Steven Bradbury, Director Environmental Fate and Effects Division Office.
Endocrine Screening – Phase 1 TSCA 8(e) and FIFRA 6(a)(2) Requirements A. Michael Kaplan, Ph.D. December 13, 2010 A. Michael Kaplan & Associates, LLC
1 Development & Evaluation of Ecotoxicity Predictive Tools EPA Development Team Regional Stakeholder Meetings January 11-22, 2010.
ISRTP 2009 Endocrine Workshop | 9-10 September 2009 | Washington, DC.
Comments Regarding Nipples/Areolae Retention Endpoint Barbara Neal, DABT BBL Sciences.
John C. O’Connor DuPont Haskell Laboratory for Health and Environmental Sciences The 15-Day Intact Adult Male Assay As An Alternative Tier I Screening.
RTI International is a trade name of Research Triangle Institute The International Society of Regulatory Toxicology and Pharmacology (ISRTP)
EDSP Validation Gary E.Timm Senior Technical Advisor Office of Science Coordination and Policy U.S. Environmental Protection Agency.
Cumulative Risk Assessment for Pesticide Regulation: A Risk Characterization Challenge Mary A. Fox, PhD, MPH Linda C. Abbott, PhD USDA Office of Risk Assessment.
and Environmental Risk Assessment
June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.
State of the Science of Endocrine Disrupting Chemicals – 2012 UNEP and WHO published in February, 2013 From ”Global Assement of EDCs” published 2002 to.
Assessing the Impact of Body Weight on Male and Female Pubertal Development EPA Special Study Tammy Stoker, PhD. Gamete and Early Embryo Biology Branch.
Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.
Quill Law Group LLC1 EDSP Compliance EDSP Phase 2 Policies and Procedures Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
Status of the U.S. Endocrine Disruptor Screening Program (EDSP) Status of the U.S. Endocrine Disruptor Screening Program (EDSP) September
Office of Pesticide Programs 21st Century Screening Assessment of Pesticides – A Regulatory View Vicki Dellarco, Ph.D. Senior Science Advisor Office of.
EDSP’s Approach to Test Protocol Validation Office of Science Coordination and Policy U.S. Environmental Protection Agency.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Quill Law Group LLC1 Endocrine Disruption and Personal Care Products --- Legislative Developments Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington,
Endocrine System. The endocrine system is made up of glands that release hormones into the bloodstream to control body functions such as growth, reproduction,
Endocrine System. The endocrine system is composed of glands that release hormones into the bloodstream to control body functions such as growth, reproduction,
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Quill Law Group LLC1 EDSP Compliance Timing, Procedural and Legal Issues Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 01 - INTRODUCTION.
Slide 1 of 24 EPA’s Endocrine Disruptor Screening Program (EDSP) Use of Exposure Data in Priority Setting Bill Wooge Office of Science Coordination and.
The Reproductive System
1 Tier 1 EDSP: Other Scientifically Relevant Information Barbara Neal Exponent December 13, 2010.
ELLEN MIHAICH, PH.D., DABT ENVIRONMENTAL AND REGULATORY RESOURCES ISRTP WORKSHOP DECEMBER 13, 2010 EDSP Test Guidelines and Guideline Modifications 1.
Wildlife Screens What Do They Tell Us? Dr. Pat Guiney Manager Global Safety, Regulatory & Environmental Assessment S.C. Johnson & Son, Inc. Racine, WI.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
Prof. Dr. Wolfgang Dekant Department of Toxicology University of Würzburg Germany Risk, Hazard, and Innovation.
0 Focusing on the Adverse Outcomes of ER-mediated Pathways Rodney Johnson ORD/MED McKim Conference September 16-18, 2008.
International Society of Regulatory Toxicology and Pharmacology 2009 Endocrine Workshop The Endocrine Disruptor Screening Program: What Can Screening Results.
Communications and the Endocrine Disruptor Screening Program ISRTP Workshop December 13, 2010.
Quill Law Group LLC1 EDSP Implementation Business and Legal Considerations Terry F. Quill Quill Law Group LLC 1667 K St, NW Washington, DC
EDSP: T IER 1 T ESTING I NFORMATION C OLLECTION ISRTP 2010 Endocrine Workshop EDSP Compliance December 13, 2010 Susan Ferenc, DVM, Ph.D.
Christopher J. Borgert, PhD Weight of Evidence Determinations for EPA’s EDSP ISRTP Workshop, December 13 Lister Hill Auditorium, Bethesda, MD.
Introduction to Session II: Incorporating Existing Data into the EDSP Erik R. Janus Director, Human Health Policy CropLife America.
The McKim Conferences for the Strategic Use of Testing Gitchee Gumee Conference Center Duluth, Minnesota June 27-29, 2006.
An Overview of the Objectives, Approach, and Components of ComET™ Mr. Paul Price The LifeLine Group All slides and material Copyright protected.
GLENBROOK SOUTH HIGH SCHOOL HONORS BIOLOGY UNIT 14 BEHAVIOR, ENDOCRINE SYSTEM & LEARNING.
EDSP Implementation: Concerns for the Pesticide Industry ISRTP 2009 Endocrine Workshop: The Endocrine Disruptor Screening Program: What Can Screening Results.
McKim Conference on Predictive Toxicology The Inn of Lake Superior Duluth, Minnesota September 25-27, 2007 Toxicity Pathways as an Organizing Concept Gilman.
Perspective on the current state-of-knowledge of mode of action as it relates to the dose response assessment of cancer and noncancer toxicity Jennifer.
Endocrine & Reproductive System Notes. Endocrine System Consists of the glands that release their products (hormones) into the bloodstream These products.
Acute Toxicity Studies Single dose - rat, mouse (5/sex/dose), dog, monkey (1/sex/dose) 14 day observation In-life observations (body wt., food consumption,
Endocrine Disruptor Screening and Testing: An Industry Update
FIFRA SAP Meeting February 2, 2010
Making it more relevant! Higher-tier data and Weight of Evidence Day 2. Adam Peters and Graham Merrington 2017.
Susan Makris U.S. EPA, Office of Research and Development
Decision Contexts in a Changing Toxicology Paradigm
Mammalian Tier I EDSP Screening Assays: What do they tell us?
Wah, Dude! Objective: To learn the structure and function of the Reproductive & Endocrine Systems Bell Work: Put the terms in the correct order from.
Presentation transcript:

What Information Fulfills EDSP Screening Requirements? Steve Levine, Ph.D. Science Fellow Ecotoxicology & Risk Assessment Monsanto Company ISRTP Meeting September 9, 2009

Topics Covered Background on the EDSP EDSTAC recommendations Functional equivalence and Other Scientifically Relevant Information (OSRI) International Regulatory Guideline Studies TOX ECOTOX WoE approaches

Tier 1 Screening The number of substances planned for Tier 1 screening is staggering Pesticides Commercial chemicals Cosmetic ingredients Food additives Nutritional supplements Certain mixtures Therefore, screening must be efficient, robust, and predictive at identifying potential EACs

EDSTAC Framework Priority setting Tier 1 screening Tier 2 testing Based on potential human exposure residues in food and drinking water residential occupational Higher priority given to chemicals likely to have human exposure via multiple pathways Tier 1 screening In vitro and in vivo assays Identify chemicals that can potentially interact with the endocrine system Tier 2 testing Will establish the relationship between dose of an EAC and the potential effects observed Assess risks humans and wildlife

EDSTAC Recommendations Recommended a minimal number of screens & tests to make sound decisions, thereby, reducing the time needed to make decisions T1S screens should be MoA based to identify specific types of endocrine activity Should be broadly predictive (sensitivity & specificity) Should produce data that can be interpreted as either positive or negative (minimize Type I & II error rates) Should be inexpensive and relatively quick and easy to perform

Tier 1 Screening Battery In vitro Estrogen receptor binding Estrogen receptor TA Androgen receptor binding Steroidogenesis (H295R) Aromatase In vivo Uterotrophic (rat) Hershberger (rat) Pubertal female (rat) Pubertal male (rat) Amphibian metamorphosis Fish short-term reproduction Many of the T1S assays meet the aforementioned criteria but others suffer from lack of specificity for adverse effects by an ED mechanism

Alternative Means to Meet Tier 1 Screening EDSTAC recommended that it should be permissible to meet T1S requirements by submitting data that are “functionally equivalent” to the data generated by the T1S battery Functionally equivalent information could be submitted for one or more of the recommended T1S assays or for the entire battery Pointed out that functionally equivalent information exists for chemicals that have reproductive and developmental toxicity testing Provisions to cite existing data in policies and procedures document

Functional Equivalence & OSRI Functional equivalence = data of a suitable nature and quality even if different methods were used i.e., provides the same essential predictive information as T1S OSRI = information that informs the determination as to whether the substance may have a similar effect produced by a substance that interacts with EAT systems OSRI may either be (1) functionally equivalent to information obtained from the Tier 1 assays or (2) data from assays that perform the same procedure / function as EDSP Tier 1 Screens 3rd bullet – equivalent or identical endpoint

EPA’s Approach for Considering OSRI Overview paper @ www.regulations.gov Anyone may submit OSRI not just Test Order Recipients Submitters should provide the information or cite previously submitted information Information will receive different weights in a WoE - the quality of the information will weigh heavily Factors will include sensitivity, specificity, confidence in the conclusions and applicability across taxa Factors will also include route & duration/frequency of administration, dose levels, age at exposure, species, number of test units, variability, and whether the data provides a basis for conclusions for potential interaction with the endocrine system in mammalian and non-mammalian systems OSRI for Tier 1 or Tier 2: metabolism, carcinogenicity, reproductive and developmental, and toxicogenomic

OSRI from OPPTS and OECD Tests TOXICOLOGY Sub-chronic (OPPTS 870.3100) Chronic (OPPTS 870.4100) Developmental/Teratology (OPPTS 870.3700) 2-gen reproduction (OPPTS 870.3800) ECOTOXICOLOGY Avian reproduction (OPPTS 850.2300) Chronic invert reproduction (OPPTS 850.1300/1350) Early Life-stage (OPPTS 850.1400) Fish full life-cycle (OPPTS 850.1500)

OSRI Will Include Toxicity tests following international regulatory guidelines where full histopathology is carried out on: Endocrine tissues (pituitary, thyroid, parathyroid, pancreas adrenal, ovary and testis) Hormone sensitive male tissues (prostate, epididymides, seminal vesicles) Hormone sensitive female tissues (mammary, uterus and reproductive tract) And toxicity protocols that focus on reproduction, fertility and development for mammalian species and other taxa (birds, fish) These studies provide the strongest evidence of potential endocrine effects and should be weighted above less comprehensive data

Rat Multi-Gen The 1996 USEPA guideline for a multiple generation reproductive and developmental toxicity assay was revised to include developmental benchmarks predictive of ED potential A diverse set of female endpoints (ovaries, uterus, vagina, and mammary glands) Day of vaginal opening and first estrus Mating and fertility indices number of implantation sites, estrous cyclicity Male tissue weights and histopathology (testes, epididymis, prostate, and seminal vesicles) and other male parameters (sperm number and analyses) FIX

Bridging OSRI to T1S Assays High concordance between the results of rat multi-gen and the rat Uterotrophic assay Consistency between MEDs for the Uterotrophic assay and estrogen-related LOEL/LOAEL in multi-generation testing High concordance between the Uterotrophic assay and the ER binding assay & the stably transfected TA for a large number of chemicals 2-gen data should meet the requirement for the pubertal assays: Pubertal assays largely have redundant endpoints with the 2-gen study Building the bridge - Similar comments can be made for the Hershberger assay – rationale for pubertals

OSRI to T1S Assays - ECOTOX Avian reproduction studies Gold standard or highest tier of avian testing Bobwhite quail and mallard duck Studies do not include exposure during all relevant stages of development or organ histopathology However, provides valuable information in a WoE context to assess potential effects of endocrine active substances Sensitivity of 1-gen vs 2-gen Japanese quail? Reproduction study design Dietary exposure for ~10 weeks prior egg-laying Photoperiod change initiates egg-laying Exposure continues for ≥8 weeks Endpoints: eggs laid, eggs damaged, eggs set, egg shell thickness, viable embryos, live embryos, hatchlings, 14-day survivors, eggs laid/female, eggs laid/female/day, 14-day survivors/female Make point regarding why these studies were developed and embryo toxicity

OSRI to T1S Assays - ECOTOX Fish full life cycle (FFLC) study Gold standard for aquatic vertebrate ecotox testing Entire LC is exposed = most sensitive life-stage is tested ~260 to 300 days for FTHD minnows = T1S spp. FFLC study design ELS → growth & repro → ELS First gen: hatching success, time-to-hatch, survival, growth and development, reproductive success (# of spawns, # of eggs) Second-gen: time-to-hatch, survival, growth and development Compare with 21-day screening assay

Principles for Evaluating Data in a WoE . Consistent pattern of responses for a MoA (+ or -) The nature and range of the biological effects observed The shape of DRCs curves when available The severity and magnitude of the effects Interpretation made in the context of biological significance & biological plausibility The presence or absence of responses in multiple taxa Evaluate results in the context of natural variability using control data (historical and concurrent)

Principles for Evaluating Data in a WoE Results from apical assays (MTD dose) need to be weighted appropriately when accompanied by decreases in BW or other potential confounders In vivo results generally are considered to have more weight than in vitro results Available in vitro assays should not be used as yes/no determinants to proceed to Tier 2 (ER binding example) SARs = critical step in the WoE process A WoE approach for OSRI must be developed along with the WoE framework for the T1S

Closing Thoughts SARs are OSRI and weighted appropriately There will be instances where OSRI will meet all or some of the T1S requirements, particularly for food use pesticides. Development of a transparent WoE approach is desperately needed not only in the interpretation of OSRI but for the T1S data before testing is required.